MEI Pharma, Inc.
MEIP
Price:
$3.0401
Market Cap:
$20.26M
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical tr...[Read more]
Industry
Biotechnology
IPO Date
2003-12-18
Stock Exchange
NASDAQ
Ticker
MEIP
The ROE as of September 2024 (TTM) for MEI Pharma, Inc. (MEIP) is 48.32%
According to MEI Pharma, Inc.’s latest financial reports and current stock price. The company's current ROE is 48.32%. This represents a change of -2539.70% compared to the average of -1.98% of the last 4 quarters.
MEI Pharma, Inc. (MEIP) Historical ROE (quarterly & annually)
How has MEIP ROE performed in the past?
The mean historical ROE of MEI Pharma, Inc. over the last ten years is -68.89%. The current 48.32% ROE has changed -170.14% with respect to the historical average. Over the past ten years (40 quarters), MEIP's ROE was at its highest in in the September 2023 quarter at 69.29%. The ROE was at its lowest in in the March 2021 quarter at -69.64%.
Average
-68.89%
Median
-59.45%
Minimum
-129.30%
Maximum
5.25%
MEI Pharma, Inc. (MEIP) ROE by Quarter and Year
Discovering the peaks and valleys of MEI Pharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 107.84%
Maximum Annual ROE = 5.25%
Minimum Annual Increase = -1611.95%
Minimum Annual ROE = -129.30%
| Year | ROE | Change |
|---|---|---|
| 2023 | -129.30% | 23.80% |
| 2022 | -104.44% | -14.59% |
| 2021 | -122.27% | 107.84% |
| 2020 | -58.83% | 67.65% |
| 2019 | -35.09% | -55.81% |
| 2018 | -79.41% | -1611.95% |
| 2017 | 5.25% | -110.49% |
| 2016 | -50.09% | -8.40% |
| 2015 | -54.68% | -8.98% |
| 2014 | -60.07% | 87.27% |
MEI Pharma, Inc. (MEIP) Average ROE
How has MEIP ROE performed in the past?
The current ROE of MEI Pharma, Inc. (MEIP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-118.67%
5-year avg
-89.99%
10-year avg
-68.89%
MEI Pharma, Inc. (MEIP) ROE vs. Peers
How is MEIP’s ROE compared to its peers?
MEI Pharma, Inc.’s ROE is greater than Magenta Therapeutics, Inc. (-61.71%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than Vincerx Pharma, Inc. (-276.65%), greater than Avenue Therapeutics, Inc. (-749.10%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Instil Bio, Inc. (-55.57%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Achilles Therapeutics plc (-47.36%), greater than Ocular Therapeutix, Inc. (-62.56%), less than Spero Therapeutics, Inc. (20.70%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Zura Bio Limited (-35.45%), greater than Phio Pharmaceuticals Corp. (-142.68%), greater than ZyVersa Therapeutics, Inc. (-172.51%), greater than TransCode Therapeutics, Inc. (-597.47%),
| Company | ROE | Market cap |
|---|---|---|
| -61.71% | $42.44M | |
| -54.50% | $41.60M | |
| -276.65% | $21.62M | |
| -749.10% | $3.91M | |
| -121.55% | $113.14M | |
| -47.64% | $8.20M | |
| -55.57% | $420.02M | |
| -27.44% | $95.30M | |
| -47.36% | $28.99M | |
| -62.56% | $1.36B | |
| 20.70% | $72.97M | |
| -24.63% | $153.20M | |
| -51.77% | $167.24M | |
| -122.70% | $1.21B | |
| -68.93% | $373.90M | |
| -39.58% | $661.50M | |
| -243.91% | $1.50M | |
| -35.45% | $230.22M | |
| -142.68% | $2.80M | |
| -172.51% | $2.54M | |
| -597.47% | $4.49M |
Build a custom stock screener for MEI Pharma, Inc. (MEIP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MEI Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
MEI Pharma, Inc. (MEIP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like MEI Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is MEI Pharma, Inc.'s ROE?
How is the ROE calculated for MEI Pharma, Inc. (MEIP)?
What is the highest ROE for MEI Pharma, Inc. (MEIP)?
What is the 3-year average ROE for MEI Pharma, Inc. (MEIP)?
What is the 5-year average ROE for MEI Pharma, Inc. (MEIP)?
How does the current ROE for MEI Pharma, Inc. (MEIP) compare to its historical average?